X-ray Induced Persistent Type I Photodynamic Therapy with Enhanced Hypoxia Tolerance and Chemoradiotherapy
Source abstract
Abstract
The hypoxic tumor microenvironment (TME), inadequate penetration depth of Vis/NIR light, and lack of sustaining reactive oxygen species (ROS) production capability of photosensitizers pose significant obstacles to the widespread clinic applications of photodynamic therapy (PDT). Herein, we developed a “persistent type I X-PDT” platform to simultaneously overcome these three limitations. Such a nanoplatform could generate efficient ROS ( • OH and O 2 •– ) under X-ray irradiation in both normoxic and hypoxic environments. The ROS production persists in tumor cells for more than 4 h, even after the X-ray source is removed. Notably, the persistent type I X-PDT does not increase the levels of hypoxia-inducible factor-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) in tumor cells both in vitro and in vivo . Moreover, to further enhance the radiotherapy efficacy in hypoxic conditions, a Pt (IV) prodrug was also introduced, which can be reduced to cisplatin selectively in tumor cells, functioning not only as a chemodrug but also as a radiosensitizer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Photoacoustic and Ultrasonic Imaging
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
New Cornerstone Science Laboratory, MOE Key Laboratory for Analytical Science of Food Safety and Biology, College of Chemistry
Fuzhou University
Department of Chemical and Biomolecular Engineering
National University of Singapore
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China
References (50)
Show source-provided references
1. 10.1021/acsmaterialslett.3c0093310.1021/acsmaterialslett.3c00933 ↗
2. 10.1039/D4TB00099D10.1039/D4TB00099D ↗
3. 10.1002/adma.20180200610.1002/adma.201802006 ↗
4. 10.1002/anie.20160413010.1002/anie.201604130 ↗
5. 10.1016/j.cej.2022.14122410.1016/j.cej.2022.141224 ↗
6. 10.1021/jacs.0c0073410.1021/jacs.0c00734 ↗
7. 10.1002/adma.20230524310.1002/adma.202305243 ↗
8. 10.1038/ncomms178610.1038/ncomms1786 ↗
9. 10.1016/j.nantod.2022.10137610.1016/j.nantod.2022.101376 ↗
10. 10.1016/S1535-6108(04)00115-110.1016/S1535-6108(04)00115-1 ↗
11. 10.1016/S0167-8140(03)00011-210.1016/S0167-8140(03)00011-2 ↗
12. 10.1016/j.immuni.2020.05.00110.1016/j.immuni.2020.05.001 ↗
13. 10.3389/fcell.2021.72996510.3389/fcell.2021.729965 ↗
14. 10.1002/anie.20230035610.1002/anie.202300356 ↗
15. 10.1186/s12917-021-02924-810.1186/s12917-021-02924-8 ↗
16. 10.1021/acsnano.4c0317210.1021/acsnano.4c03172 ↗
17. 10.1021/jacs.3c1438710.1021/jacs.3c14387 ↗
18. 10.1021/cr500419810.1021/cr5004198 ↗
19. 10.1002/smll.20150192310.1002/smll.201501923 ↗
20. 10.1039/D2NR01847K10.1039/D2NR01847K ↗
21. 10.1002/adfm.20150480310.1002/adfm.201504803 ↗
22. 10.1038/ncomms978510.1038/ncomms9785 ↗
23. 10.1021/acsnano.9b0108710.1021/acsnano.9b01087 ↗
24. 10.1002/adma.20140514110.1002/adma.201405141 ↗
25. 10.1039/C7NH00087A10.1039/C7NH00087A ↗
26. 10.1038/s41467-020-15591-410.1038/s41467-020-15591-4 ↗
27. 10.1039/D1QM01475G10.1039/D1QM01475G ↗
28. 10.1016/j.cej.2018.07.04910.1016/j.cej.2018.07.049 ↗
29. 10.1016/j.canlet.2014.12.05210.1016/j.canlet.2014.12.052 ↗
30. 10.1021/acsnano.8b0785210.1021/acsnano.8b07852 ↗
31. 10.1038/s41467-024-46768-w10.1038/s41467-024-46768-w ↗
32. 10.1002/adma.20210397810.1002/adma.202103978 ↗
33. 10.1002/adma.20210362710.1002/adma.202103627 ↗
34. 10.1038/s41467-023-41389-110.1038/s41467-023-41389-1 ↗
35. 10.1002/anie.20240439510.1002/anie.202404395 ↗
36. 10.1002/adfm.20200116610.1002/adfm.202001166 ↗
37. 10.1021/acsnano.2c0728610.1021/acsnano.2c07286 ↗
38. 10.1016/j.cej.2022.13732010.1016/j.cej.2022.137320 ↗
39. 10.1002/adma.20200788810.1002/adma.202007888 ↗
40. Liu J. · 2025 · 50710.1002/9783527845347.ch15 ↗
41. 10.1021/acsnano.6b0140110.1021/acsnano.6b01401 ↗
42. 10.1038/nnano.2015.1710.1038/nnano.2015.17 ↗
43. 10.1021/ja304986t10.1021/ja304986t ↗
44. 10.1126/sciadv.aba300910.1126/sciadv.aba3009 ↗
45. 10.3390/ijms2206314010.3390/ijms22063140 ↗
46. 10.1038/s41586-021-03251-610.1038/s41586-021-03251-6 ↗
47. 10.1021/acs.nanolett.0c0494010.1021/acs.nanolett.0c04940 ↗
48. 10.1021/acsami.8b0001510.1021/acsami.8b00015 ↗
49. 10.1016/j.actbio.2022.10.04910.1016/j.actbio.2022.10.049 ↗
50. 10.1126/sciadv.abc526710.1126/sciadv.abc5267 ↗